{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:25:31Z","timestamp":1789719931615,"version":"4.0.1"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"ITM Isotope Technologies Munich SE"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.nucmedbio.2025.109031","type":"journal-article","created":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T18:05:56Z","timestamp":1748801156000},"page":"109031","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Exploration of the utilization of irreversible cysteine protease inhibitor in FAP-targeted radiopharmaceuticals design to increase tumor residence time"],"prefix":"10.1016","volume":"146-147","author":[{"given":"Katie","family":"Brake","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audif\u00e1s-Salvador","family":"Matus-Meza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Purnima","family":"Rawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedram","family":"Rikhtechi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiana Sherkat","family":"Sadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jered C.","family":"Garrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2025.109031_bb0005","doi-asserted-by":"crossref","first-page":"840","DOI":"10.3390\/ijms20040840","article-title":"Targeting tumor microenvironment for cancer therapy","volume":"20","author":"Roma-Rodrigues","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.nucmedbio.2025.109031_bb0010","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1007\/s00259-022-05706-y","article-title":"Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond","volume":"49","author":"Li","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2025.109031_bb0015","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1158\/1078-0432.CCR-20-4226","article-title":"Molecular features of cancer-associated fibroblast subtypes and their implication on cancer pathogenesis, prognosis, and immunotherapy resistance","volume":"27","author":"Galbo","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2025.109031_bb0020","doi-asserted-by":"crossref","first-page":"123","DOI":"10.4161\/cbt.13.3.18696","article-title":"Fibroblast activation protein: a potential therapeutic target in cancer","volume":"13","author":"Liu","year":"2012","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.nucmedbio.2025.109031_bb0025","doi-asserted-by":"crossref","first-page":"101417","DOI":"10.1016\/j.smim.2020.101417","article-title":"Fibroblast heterogeneity in tumor micro-environment: role in immunosuppression and new therapies","author":"Mhaidly","year":"2020","journal-title":"Semin Immunol"},{"key":"10.1016\/j.nucmedbio.2025.109031_bb0030","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/prca.201300095","article-title":"Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy","volume":"8","author":"Hamson","year":"2014","journal-title":"PROTEOMICS\u2013Clinical Applications"},{"key":"10.1016\/j.nucmedbio.2025.109031_bb0035","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.648187","article-title":"Fibroblast activation protein-alpha as a target in the bench-to-bedside diagnosis and treatment of tumors: a narrative review","volume":"11","author":"Xin","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.nucmedbio.2025.109031_bb0040","doi-asserted-by":"crossref","first-page":"5744","DOI":"10.3390\/cancers13225744","article-title":"Radioligands targeting fibroblast activation protein (FAP)","volume":"13","author":"Lindner","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.nucmedbio.2025.109031_bb0045","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","article-title":"Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein","volume":"59","author":"Lindner","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2025.109031_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41181-019-0069-0","article-title":"Targeting of activated fibroblasts for imaging and therapy","volume":"4","author":"Lindner","year":"2019","journal-title":"EJNMMI Radiopharmacy and Chemistry"},{"key":"10.1016\/j.nucmedbio.2025.109031_bb0055","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2967\/jnumed.118.224469","article-title":"Development of fibroblast activation protein\u2013targeted radiotracers with improved tumor retention","volume":"60","author":"Loktev","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2025.109031_bb0060","doi-asserted-by":"crossref","first-page":"618","DOI":"10.2967\/jnumed.122.264941","article-title":"Three-time-point PET analysis of 68Ga-FAPI-46 in a variety of cancers","volume":"64","author":"Naeimi","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2025.109031_bb0065","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.2967\/jnumed.119.236786","article-title":"Radiation dosimetry and biodistribution of 68Ga-FAPI-46 PET imaging in cancer patients","volume":"61","author":"Meyer","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2025.109031_bb0070","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2967\/jnumed.121.262096","article-title":"68Ga-FAPI as a diagnostic tool in sarcoma: data from the 68Ga-FAPI PET prospective observational trial","volume":"63","author":"Kessler","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2025.109031_bb0075","first-page":"727","article-title":"Initial clinical experience with 90Y-FAPI-46 radioligand therapy for advanced-stage solid tumors: a case series of 9 patients","volume":"63","author":"Ferdinandus","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2025.109031_bb0080","doi-asserted-by":"crossref","DOI":"10.1097\/RLU.0000000000003810","article-title":"Feasibility and therapeutic potential of 177Lu\u2013fibroblast activation protein inhibitor\u201346 for patients with relapsed or refractory cancers: a preliminary study","volume":"46","author":"Assadi","year":"2021","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.nucmedbio.2025.109031_bb0085","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.2967\/jnumed.122.264036","article-title":"A dimeric FAP-targeting small-molecule radioconjugate with high and prolonged tumor uptake","volume":"63","author":"Galbiati","year":"2022","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1016\/j.nucmedbio.2025.109031_bb0090","first-page":"1","article-title":"Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides","author":"Millul","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2025.109031_bb0095","first-page":"476","article-title":"Fibroblast activation protein (FAP) targeting homodimeric FAP inhibitor radiotheranostics: a step to improve tumor uptake and retention time","volume":"11","author":"Moon","year":"2021","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2025.109031_bb0100","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1021\/acs.bioconjchem.2c00214","article-title":"Examination of charge modifications of an endolysosomal trapping inhibitor in an antagonistic NTSR1-targeted construct for colon cancer","volume":"33","author":"Fan","year":"2022","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2025.109031_bb0105","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.ejmech.2019.05.068","article-title":"Enhanced tumor retention of NTSR1-targeted agents by employing a hydrophilic cysteine cathepsin inhibitor","volume":"177","author":"Fan","year":"2019","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.nucmedbio.2025.109031_bb0110","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2967\/jnumed.119.231282","article-title":"Development of improved tumor-residualizing, GRPR-targeted agents: preclinical comparison of an endolysosomal trapping approach in agonistic and antagonistic constructs","volume":"61","author":"Zhang","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2025.109031_bb0115","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.tips.2007.10.011","article-title":"Cysteine cathepsin proteases as pharmacological targets in cancer","volume":"29","author":"Palermo","year":"2008","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.nucmedbio.2025.109031_bb0120","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bbapap.2011.10.002","article-title":"Cysteine cathepsins: from structure, function and regulation to new frontiers","volume":"1824","author":"Turk","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.nucmedbio.2025.109031_bb0125","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3390\/cells8030264","article-title":"Cysteine cathepsins and their extracellular roles: shaping the microenvironment","volume":"8","author":"Vidak","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.nucmedbio.2025.109031_bb0130","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2101852118","article-title":"An ultra-high-affinity small organic ligand of fibroblast activation protein for tumor-targeting applications","volume":"118","author":"Millul","year":"2021","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.nucmedbio.2025.109031_bb0135","doi-asserted-by":"crossref","first-page":"14028","DOI":"10.1021\/acs.jmedchem.1c01010","article-title":"Regulation of fibroblast activation protein-\u03b1 expression: focus on intracellular protein interactions","volume":"64","author":"Juillerat-Jeanneret","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2025.109031_bb0140","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/(SICI)1097-0282(1999)51:1<99::AID-BIP11>3.0.CO;2-R","article-title":"Structural basis of inhibition of cysteine proteases by E-64 and its derivatives","volume":"51","author":"Matsumoto","year":"1999","journal-title":"Pept Sci"},{"key":"10.1016\/j.nucmedbio.2025.109031_bb0145","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1021\/jm500031w","article-title":"Extended structure\u2013activity relationship and pharmacokinetic investigation of (4-quinolinoyl) glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP)","volume":"57","author":"Jansen","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2025.109031_bb0150","first-page":"1","article-title":"Fibroblast activation protein targeted therapy using [177Lu]FAPI-46 compared with [225Ac]FAPI-46 in a pancreatic cancer model","author":"Liu","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2025.109031_bb0155","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1134\/S1607672916050033","article-title":"Expression of the FAP gene in non-fibroblast human cell lines. Development of cancer-associated fibroblast models","author":"Tyulkina","year":"2016","journal-title":"Dokl Biochem Biophys"},{"key":"10.1016\/j.nucmedbio.2025.109031_bb0160","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s11596-023-2740-7","article-title":"Establishment of FAP-overexpressing cells for FAP-targeted theranostics","volume":"43","author":"Jian","year":"2023","journal-title":"Curr Med Sci"},{"key":"10.1016\/j.nucmedbio.2025.109031_bb0165","first-page":"2593","article-title":"Fibroblast activation protein-\u03b1 in tumor cells promotes colorectal cancer angiogenesis via the Akt and ERK signaling pathways","volume":"17","author":"Cao","year":"2018","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.nucmedbio.2025.109031_bb0170","doi-asserted-by":"crossref","first-page":"840","DOI":"10.3748\/wjg.v18.i8.840","article-title":"Expression of fibroblast activation protein in human pancreatic adenocarcinoma and its clinicopathological significance","volume":"18","author":"Shi","year":"2012","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.nucmedbio.2025.109031_bb0175","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3390\/ph17020256","article-title":"Towards the magic radioactive bullet: improving targeted radionuclide therapy by reducing the renal retention of radioligands","volume":"17","author":"de Roode","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.nucmedbio.2025.109031_bb0180","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1021\/acscatal.8b05051","article-title":"Covalent inhibition mechanism of antidiabetic drugs\u2014Vildagliptin vs Saxagliptin","volume":"9","author":"Wang","year":"2019","journal-title":"ACS Catal"},{"key":"10.1016\/j.nucmedbio.2025.109031_bb0185","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1084\/jem.20130110","article-title":"Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia","volume":"210","author":"Tran","year":"2013","journal-title":"J Exp Med"},{"key":"10.1016\/j.nucmedbio.2025.109031_bb0190","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1352632","article-title":"Investigating the complex interplay between fibroblast activation protein \u03b1-positive cancer associated fibroblasts and the tumor microenvironment in the context of cancer immunotherapy","volume":"15","author":"Kraxner","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.nucmedbio.2025.109031_bb0195","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3390\/pharmaceutics16030345","article-title":"Beyond small molecules: antibodies and peptides for fibroblast activation protein targeting radiopharmaceuticals","volume":"16","author":"Sun","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.nucmedbio.2025.109031_bb0200","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1007\/s00330-022-09251-y","article-title":"Usefulness of [68Ga]FAPI-04 and [18F]FDG PET\/CT for the detection of primary tumour and metastatic lesions in gastrointestinal carcinoma: a comparative study","volume":"33","author":"Li","year":"2023","journal-title":"Eur Radiol"},{"key":"10.1016\/j.nucmedbio.2025.109031_bb0205","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1080\/13543776.2021.1866539","article-title":"Therapeutic approaches targeting the neurotensin receptors","volume":"31","author":"Iyer","year":"2021","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.nucmedbio.2025.109031_bb0210","first-page":"1","article-title":"FAP-targeted radionuclide therapy with [177Lu]Lu-FAPI-46 in metastatic nasopharyngeal carcinoma","author":"Fu","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2025.109031_bb0215","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41586-024-07461-6","article-title":"Covalent targeted radioligands potentiate radionuclide therapy","volume":"630","author":"Cui","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.nucmedbio.2025.109031_bb0220","doi-asserted-by":"crossref","DOI":"10.1126\/science.1260419","article-title":"Proteomics. Tissue-based map of the human proteome","volume":"347","author":"Uhl\u00e9n","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.nucmedbio.2025.109031_bb0225","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.addr.2008.04.005","article-title":"Renal uptake and metabolism of radiopharmaceuticals derived from peptides and proteins","volume":"60","author":"Akizawa","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.nucmedbio.2025.109031_bb0230","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.drudis.2012.07.002","article-title":"Liver uptake of radiolabeled targeting proteins and peptides: considerations for targeting peptide conjugate design","volume":"17","author":"Hosseinimehr","year":"2012","journal-title":"Drug Discov Today"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096980512500040X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096980512500040X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T20:45:00Z","timestamp":1756154700000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096980512500040X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":46,"alternative-id":["S096980512500040X"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2025.109031","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploration of the utilization of irreversible cysteine protease inhibitor in FAP-targeted radiopharmaceuticals design to increase tumor residence time","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2025.109031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109031"}}